Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors, treatment and outcome.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Saarinen-Pihkala, Ulla M
G Jónsson, Ólafur
MetadataShow full item record
CitationHaematologica 2016, 101 (1):68-76
AbstractRelapse is the main reason for treatment failure in childhood acute lymphoblastic leukemia. Despite improvements in the up-front therapy, survival after relapse is still relatively poor, especially for high-risk relapses. The aims of this study were to assess outcomes following acute lymphoblastic leukemia relapse after common initial Nordic Society of Paediatric Haematology and Oncology protocol treatment; to validate currently used risk stratifications, and identify additional prognostic factors for overall survival. Altogether, 516 of 2735 patients (18.9%) relapsed between 1992 and 2011 and were included in the study. There were no statistically significant differences in outcome between the up-front protocols or between the relapse protocols used, but an improvement over time was observed. The 5-year overall survival for patients relapsing in the period 2002-2011 was 57.5±3.4%, but 44.7±3.2% (P<0.001) if relapse occurred in the period 1992-2001. Factors independently predicting mortality after relapse included short duration of first remission, bone marrow involvement, age ten years or over, unfavorable cytogenetics, and Down syndrome. T-cell immunophenotype was not an independent prognostic factor unless in combination with hyperleukocytosis at diagnosis. The outcome for early combined pre-B relapses was unexpectedly poor (5-year overall survival 38.0±10.6%), which supports the notion that these patients need further risk adjustment. Although survival outcomes have improved over time, the development of novel approaches is urgently needed to increase survival in relapsed childhood acute lymphoblastic leukemia.
DescriptionTo access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Files. This article is open access.
RightsArchived with thanks to Haematologica
- Treatment-related mortality in relapsed childhood acute lymphoblastic leukemia.
- Authors: Oskarsson T, Söderhäll S, Arvidson J, Forestier E, Frandsen TL, Hellebostad M, Lähteenmäki P, Jónsson ÓG, Myrberg IH, Heyman M, Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL Relapse Working Group.
- Issue date: 2018 Apr
- Outcome after first relapse in children with acute lymphoblastic leukemia: a population-based study of 315 patients from the Nordic Society of Pediatric Hematology and Oncology (NOPHO).
- Authors: Schroeder H, Garwicz S, Kristinsson J, Siimes MA, Wesenberg F, Gustafsson G
- Issue date: 1995 Nov
- Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies.
- Authors: Uderzo C, Dini G, Locatelli F, Miniero R, Tamaro P
- Issue date: 2000 Nov
- Survival outcome following isolated central nervous system relapse treated with additional chemotherapy and craniospinal irradiation in childhood acute lymphoblastic leukemia.
- Authors: Kumar P, Kun LE, Hustu HO, Mulhern RK, Hancock ML, Coffey D, Rivera GK
- Issue date: 1995 Feb 1
- [Multi-center trial based on SCMC-ALL-2005 for children's acute lymphoblastic leukemia].
- Authors: SHAQ Multicenter Study Group of Children's Acute Lymphoblastic Leukemia Research.
- Issue date: 2013 Jul